Known contraindication to receive cetuximab or irinotecan at the planned doses

No contraindication for surgery

Known hypersensitivity to the trial drugs or other contraindication to standard “7+3” induction chemotherapy

Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase

Any medical or physical contraindication, or other inability to undergo hematopoietic progenitor cell (HPC) collection

Surgery, unless documented contraindication

Radiotherapy, unless documented contraindication

Chemotherapy, unless documented contraindication

Contraindication to angiography or chemoembolization medications

History of thromboembolic disease or uterine cancer that is considered a contraindication to tamoxifen

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Known contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates)

Any known factors that would pose a contraindication to receiving nivolumab

Subjects with melanoma or with a history of melanoma, invasive squamous cell carcinomas, or aphakia (due to contraindication for use of methoxsalen).

History of documented anaphylaxis or contraindication to any of the study medications

Contraindication to epidural per Pain Service guidelines

All patients with tumors involving the thoracic esophagus must undergo bronchoscopy to document the absence of a fistula no known contraindication to the use of taxanes or platinum compounds

Contraindication to MRI (metal implants)

Contraindication to angiography/embolization procedure based on judgment of the treating investigator

Contraindication to MRI

Any known hypersensitivity or contraindication to the components of the study drug AZD1775

No known hypersensitivity or contraindication to the components of study treatment (M6620 [VX-970], gemcitabine)

Any known hypersensitivity or contraindication to the components of the study drug AZD1775

Participant has a contraindication to biopsy

Medical contraindication to receipt of radiotherapy

No contraindication to tumor biopsy at time of study enrollment

Active venous thrombosis with contraindication for anticoagulation

Patients in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol, in the opinion of the investigator.

For Cohorts 1, 3 and 4, contraindication to chemotherapy as first-line therapy due to patient age, comorbidity or patient preference

Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy

Contraindication to RPFNA including breast implant(s), bilateral radiation, anticoagulation (excluding those on 81 mg aspirin)

Contraindication to receiving radiotherapy

Known contraindication for topotecan or temozolomide

Patients with contraindication to use leucovorin calcium (calcium folinate), 5-fluorouracil, and oxaliplatin (FOLFOX) chemotherapy and pelvic radiation.

Contraindication to cyclophosphamide or fludarabine chemotherapy

Extensive loculations or hydropneumothorax or other contraindication to pleurodesis

Contraindication or precaution for enzalutamide

Has a contraindication (sensitivity or allergy) to trimethoprim/sulfamethoxazole and ampicillin.

Any condition that would be a contraindication to receiving trastuzumab as described in the approved local label or a condition that would prevent treatment with the physician's choice of chemotherapy

Contraindication to receive radiotherapy

Contraindication to IV contrast

Contraindication to cyclophosphamide or fludarabine chemotherapy

Patients with contraindication to thromboprophylaxis

A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging

Any contraindication to therapy with nivolumab

Medical contraindication to radiation treatment (e.g. active systemic sclerosis, other uncontrolled autoimmune condition)

Contraindication to angiography/embolization including:\r\n* Patients cannot receive contrast:\r\n** Severe allergic reaction to contrast despite premedication\r\n** Poor renal function not on dialysis\r\n* Other, based on judgment of the investigator

Colorectal patients must have received prior fluorouracil (5FU), irinotecan and oxaliplatin (any combination) or have a contraindication to receiving these agents

CRITERIA FOR SCREENING: Any known contraindication to leukapheresis

CRITERIA FOR SCREENING: Any known and irreversible contraindication to huJCAR014 therapy

CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: History or presence of clinically relevant central nervous system (CNS) pathology that, in the opinion of the PI or designee, is a contraindication to lymphodepleting chemotherapy or huJCAR014 infusion

Contraindication to the use of PTX

Has a history or current evidence of physical or physiological contraindication to participation in this study, at the discretion of the treating investigator

Patients with any contraindication to receiving rhuGM-CSF based products

Absence of contraindication for Ommaya reservoir

Any contraindication to the combination anti-cancer agent as per local prescribing information

Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines

Unable to undergo MRI of the brain (i.e. pacemaker or any other contraindication for MRIs)

Active uncontrolled infection that would be a contraindication to safe use of high-dose therapy

Contraindication to any concomitant medication, including pre-medications or hydration given prior to therapy

No contraindication to be on a minimum of 81 mg aspirin a day (or other anticoagulant therapy as prescribed) for thromboembolism prophylaxis

Contraindication to intravenous (IV) contrast

Have a contraindication to post-ASCT maintenance lenalidomide

Patients with clinical contraindication against lumbar puncture or Ommaya placement are NOT eligible for either Stratum

Contraindication to repeat breast biopsy (neoadjuvant chemotherapy group)

Patients who have contraindication to cyclophosphamide chemotherapy

Contraindication for undergoing MRIs

No contraindication to receiving radiotherapy and no known allergy to components of fresolimumab

Subjects with a contraindication to MR-HIFU.

Patients who cannot obtain a contrast-enhanced MRI or CT myelogram due to allergy, renal failure or other medical contraindication

Contraindication to general anesthesia

Contraindication to MRI scans or intravenous contrast

Medical contraindication to the use of varenicline OR nicotine patch

Medical contraindication to the use of bupropion

Any contraindication to external beam radiotherapy

Patients with documented contraindication to anticoagulation therapy such as heparin induced thrombocytopenia or a documented coagulopathy or hematologic disorder that would contraindicated undergoing treatment and use of the associated anticoagulant agents required during treatment

Patients with any contraindication to receiving rhuGM-CSF based products

Contraindication to receiving HCQ or TACE

Contraindication to or unwillingness to undergo study related procedures including a repeat bronchoscopy

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

The patient has a contraindication (e.g. sensitivity/allergy) to both trimethoprim/sulfamethoxazole and ampicillin

Contraindication or unwillingness to undergo multiple CT scans

Must have no contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.

Contraindication to receiving radiotherapy or TACE

Presenting with a general or visceral contraindication to intensive treatment including:

Known contraindication or hypersensitivity to any component of bevacizumab

Patient has a known hypersensitivity or contraindication to study products that, in the opinion of the investigator, cannot be adequately pre-medicated

Patient with contraindication for imaging with MRI

MATCHED RELATED DONOR: History of other medical conditions that in the opinion of PI constitute a contraindication to donation

HAPLOIDENTICAL RELATED DONOR: History of other medical conditions that in the opinion of PI constitute a contraindication to donation

Requires treatment with other medications that cannot be stopped and for which there is a known contraindication to co-administration of one or more of the study drugs.

Contraindication to both CT and MRI contrast agents

Have known contraindication to Gd-MRI.

DONOR: No contraindication to the administration of filgrastim (G-CSF)

Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.

Medical contraindication to apheresis

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Patients who have a contraindication to any of the required concomitant drugs or supportive treatments (including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment) are NOT eligible for participation

Contraindication to haploidentical HCT as defined by the Investigator

Patients with contraindication for treatment by laparoscopy

Any known hypersensitivity or contraindication to the components of the study drug AZD1775

Known contraindication to aromatase inhibitor or SERM therapy

Any known hypersensitivity or contraindication to the components of the study drug AZD1775 or olaparib.

Part 2: have a major contraindication to MP (e.g., allergy/hypersensitivity to study medications or their constituents), or conditions making adherence difficult as determined by the attending physician

Has a contraindication to administration of amoxicillin, ampicillin, ciprofloxacin, erythromycin, gentamycin, penicillin, trimethoprim/sulfamethoxazole, and vancomycin

Has contraindication to administration of non-steroidal anti-inflammatory drugs (NSAIDS)

Patients with a contraindication to contrast-enhanced MRI

Participants in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol, in the opinion of the investigator

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Any medical or physical contraindication or any other inability to undergo HSPC collection

Any medical or physical contraindication or other inability to undergo HSPC collection

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all available anti-microbial drugs or intolerance to IV hydration due to pre-existing pulmonary or cardiac impairment

Contraindication to cisplatin chemotherapy or plans to alter or reduce cisplatin therapy

Known contraindication to dexamethasone (allergic reaction or systemic fungal infection)

For the phase II portion, patients must have histologically and/or cytologically confirmed metastatic colorectal carcinoma that has progressed on, is intolerant of, or is inappropriate for all standard therapies; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment; prior epithelial growth factor receptor (EGFR)-targeting agent (or contraindication to these drugs) is required for subjects with K-Ras wildtype tumors

Any contraindication to the use of cisplatin, carboplatin, or paclitaxel chemotherapy

Prior systemic regimens must include previously approved therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy (if no contraindication); and if negative for KRAS, NRAS, and BRAF mutations and no contraindication, an anti-epidermal growth factor receptor (EGFR) therapy; and progressed after the last administration of approved therapy.

Subjects with bone metastases should be treated with intravenous bisphosphonates or subcutaneous denosumab (or investigator preferred standard of care) prior to and/or during the trial, unless there is a contraindication or subject intolerance to these therapies. For patients who are normocalcemic, therapy can be initiated at the time the patient initiates study drug

Contraindication to treatment for TE prophylaxis

Contraindication to any drug in the chemotherapy regimen, and specifically

Patients must have been previously treated with a taxane except in cases of contraindication (e.g. poor performance status, age or patient choice)

DONOR: Any contraindication to the administration of subcutaneous G-CSF at a dose of 16 mg/kg/day for 5 consecutive days

Has a contraindication to administration of ampicillin or trimethoprim/ sulfamethoxazole.

Any contraindication to oral agents.

Known or suspected hypersensitivity to ofatumumab or SB-485232 that in the opinion of the investigator is a contraindication to their participation in the study

Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy

Medical contraindication to undergoing MR imaging

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, or antiviral drugs

Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)

Contraindication to all available herpes simplex virus (HSV)/varicella prophylactic antiviral drugs

Patients who have contraindication to MRI

For stratum C, patients must have received prior anthracycline therapy anthracycline (or have a contraindication to anthracycline) or gemcitabine-based therapy (or have a contraindication to gemcitabine)

Contraindication to dexamethasone or any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment

Has a contraindication to administration of trimethoprim/sulfamethoxazole or ampicillin.

Subject has a contraindication to receiving IM injections (eg, bleeding disorders, anticoagulant use).

Subjects with a known allergy to polyethylene glycol hydrogel (spacer material) or contraindication to spacer products (Duraseal or SpaceOAR)

Any contraindication to ECP, i.e. contraindication to heparin or methoxsalen (8-MOP)

Has a contraindication to administration of trimethoprim/sulfamethoxazole or ampicillin.

Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase.

Clear contraindication for systemic corticosteroids (diabetes mellitus is not per se a clear contraindication);

Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Patients with contraindication to thromboprophylaxis

Contraindication to MRI

No contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Participants with contraindication to RT while adjuvant RT is clinically indicated

Contraindication to any concomitant medication, including antivirals or anticoagulation

Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy.

Has a known hypersensitivity, intolerability or contraindication to any component of study treatment, including premedication

Contraindication to any concomitant medication, including antivirals or anticoagulation

Contraindication to heparin as per NCCN guidelines

Contraindication to corticosteroids

Contraindication to EUS-guided needle puncture into the pancreas

Medical contraindication to biopsy of target lesion

Patients with contraindication to steroid use

Contraindication to chemotherapy or radiation

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Any contraindication or known allergy or hypersensitivity to any study drugs

Contraindication to gadolinium-enhanced MRI imaging

Patients with a contraindication (e.g. sensitivity/allergy) to trimethoprim/sulfamethoxazole or ampicillin

Contraindication to any concomitant medication, including antivirals or anticoagulation

Subjects with bone metastases should be treated with intravenous bisphosphonates or subcutaneous denosumab (or investigator preferred standard of care) prior to and during the trial, unless there is a contraindication or subject intolerance to these therapies

Any contraindication for TACE.

Any contraindication for doxorubicin administration:

Subjects with an absolute contraindication to corticosteroid administration

Patients with locally advanced BCC are required to have disease that is considered inoperable due to significant functional compromise or to have a medical contraindication to surgery

Previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy, an anti-VEGF therapy (if no contraindication) and if KRAS wild type and no contraindication, an anti-EGFR therapy.

Any known hypersensitivity or contraindication to the components of study treatment

Known contraindication to standard-of-care sorafenib including allergic reaction, pill swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant GI bleed within 30 days, renal failure including dialysis

Contraindication to propranolol, etodolac

Patients with any known contraindication to treatment with, including hypersensitivity to quinacrine or erlotinib

Contraindication to concomitant anticoagulation prophylaxis

Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or edoxaban;

Any contraindication to MRI examination

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients

Contraindication to receive vincristine or any planned protocol-specified chemotherapy

Known contraindication to intravenous gadolinium contrast administration (e.g., renal impairment, known allergy); standard institutional policies on gadolinium and renal function will be followed

Contraindication to potential treatment agents

Patient must have no contraindication for CT with iodinated contrast

Known hypersensitivity or contraindication to study drugs, oxazolidinones, or quinolones.

Known contraindication to dexamethasone

Contraindication to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir)

Contraindication to any of the required concomitant drugs or supportive treatments, including antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

Known sensitivity or contraindication to any component of study treatment

Contraindication for all comparators:

Patients with contraindication to dexamethasone.

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.

Any contraindication to gemcitabine therapy

Known or suspected hypersensitivity to ofatumumab or bendamustine that in the opinion of the investigator is a contraindication to their participation in the present study.

Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents, or other contraindication to gadolinium contrast and other known contraindication to MRI;

Contraindication for nicotine patch use

Physical or psychological contraindication to participation at the discretion of the treating physician

History of documented anaphylaxis or contraindication to any of the study medications

PHASE II: Any medical contraindication to exercise according to a physician or physician’s designee

Connective tissue disorders, e.g. scleroderma, that in the opinion of the treating physicians is a contraindication to radiation therapy

Contraindication or allergy to intravenous lidocaine

Subject, as deemed by treating investigator has contraindication to endoscopy or Spray Cryotherapy Procedure.

Any contraindication to cardiac stress testing

Patients with any pre-existing medical conditions that would be a contraindication to exercise

Absolute contraindication to intravenous iodinated contrast (history [Hx] of significant previous contrast reaction, not mitigated by appropriate pre-medication)

Patients with a history of hypersensitivity to dexamethasone or having any contraindication to physical activity as determined by the treating physician

Major contraindication to methylphenidate i.e. hypersensitivity

Contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function

Major contraindication to fish oil i.e. hypersensitivity to fish/oil or physical activity

Medical contraindication to exercise

Contraindication to use of non-steroidal anti-inflammatory drug (NSAID), acetaminophen or IV opioids

Pregnant patients will not be included in the study as pregnancy is a relative contraindication for these types of surgical procedures

Major contraindication to ginseng: allergy/hypersensitivity to Panax species or their constituents (history of arrhythmias, agitation, or motor tics, or severe angina pectoris)

Contraindication to placement of an IPC (e.g., uncorrected coagulopathy)

Known contraindication to receiving G-CSF

Hypersensitivity/allergy or contraindication to any component of the stent, delivery system, or medication required to complete the procedure,which in the investigator's opinion cannot be adequately premedicated

Allergy or other contraindication to morphine sulfate

Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product

The allogeneic PBSC donor has a contraindication to statin treatment

Participant has allergy or other contraindication for morphine or gabapentin therapy

Do not have a contraindication to MRI (i.e., pacemaker)

Contraindication to gadolinium (Gd) contrast agents

Patients with contraindication to the intravenous use of iodinated contrast agent (i.e. allergy to iodinated contrast or severely impaired renal function with a creatinine level >= 1.3)

Women who have a contraindication to the intravenous use of iodinated contrast agent (i.e., allergy to iodinated contrast or severely impaired renal function with a creatinine level >= 1.3)

Contraindication for the nicotine patch (e.g., heart attack, angina, skin allergies) unless a doctor’s note is provided.

Contraindication to NRT;

The allogeneic PBSC donor has a contraindication to statin treatment

Medical contraindication to receipt of radiotherapy

Any contraindication for GVHD prophylaxis with mycophenolate mofetil, cyclosporine A, or tacrolimus

No known contraindication to NSAID use

Have no contraindication to NRT

Have a contraindication to NRT

Patients who have a contraindication to radiation therapy

Presence of any contraindication for a neurosurgical procedure

contraindication to anticoagulant therapy

Has contraindication to MRI contrast

Women who have a contraindication to the intravenous use of iodinated contrast agent (i.e., allergy to iodinated contrast or severely impaired renal function with a creatinine level > 1.3 or estimated glomerular filtration rate [eGFR] >= 45)

Patients with a contraindication to sedation or general anesthesia

Patients with a contraindication to sedation or general anesthesia

Patient must not have contraindication to iodinated contrast

Contraindication to MRI

Contraindication to PET

Excluded from this study will be prisoners, pregnant women, patients with a contraindication for additional lung biopsies, and patients who cannot give informed consent (language barrier, cognitive impairment, etc.)

Subjects who have a contraindication for 3Tesla (3T) MRI, or have an allergy to gadolinium containing contrast material

Patients with a contraindication to gadolinium based contrast agents, including allergy or impaired renal function (per UW health guidelines)

Any other contraindication to CT with iodinated contrast, as CT with contrast will be used in the study

Contraindication to Lasix

Contraindication to MRI scan (i.e. due to cardiac pacemaker)

Any contraindication to bronchoscopy, for example:

Contraindication to general anesthesia

Inability or contraindication to undergo transcatheter arterial embolization

Contraindication to CT or MRI contrast

Patients with a contraindication to contrast-enhanced MRI

Patients with a malignancy within the past 3 years for which study drugs or a prostatectomy is a contraindication

Known hypersensitivity to glucagon (contraindication for glucagon IV, required for endorectal MRI only)

Pheochromocytoma, insulinoma or galactosemia (contraindication for glucagon IV, required for endorectal MRI only)

Insulin?dependent diabetes (contraindication for glucagon IV, required for endorectal MRI only)

Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines

Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines

Contraindication to MRI

Contraindication to PET

Subject who is deemed by the treating physician to have a contraindication to definitive treatment

Subjects with a contraindication to receiving gadolinium containing contrast for the MRI

Contraindication to MRI or history of adverse reaction to gadolinium

Contraindication for MP MRI

Patients who have presence of a known contraindication to DCE-MRI may not participate in that portion of the study:\r\n* Known reaction to gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA), contrast agent \r\n* Chronic kidney disease\r\n* Nursing women

Contraindication to use of gadolinium based intravenous contrast, including life threatening allergy or compromised renal function (creatinine > 2.0)

Known intolerance, hypersensitivity, or contraindication to glucocorticoids.

Contraindication to any of the required concomitant drugs or supportive treatments.

Contraindication or allergy to Feraheme (based on insert)

Contraindication to MRI

Contraindication to potassium iodide

Contraindication to prostate mpMRI (renal failure, hip prosthesis, pacemaker, etc)

Contraindication to prostate biopsy via transrectal or transperineal approaches (including coagulopathy)

Contraindication for or inability to tolerate MRI examination

Contraindication to use of fluoropyrimidines as a radiosensitizing agent

Contraindication to prostate biopsy

Patient with known severe adverse drug reaction or contraindication to Gadolinium-Based Contrast Agent

Contraindication to MRI (metal implants)

Claustrophobia or any other contraindication to MRI imaging evaluated by a standardized safety questionnaire

Contraindication for oral potassium iodine administration

Patient who has a contraindication to endoscopy

Any known hypersensitivity or contraindication to the components of study treatment

Have no contraindication to short-term atorvastatin therapy

History of any condition deemed by the principal investigator to be a contraindication to B-WARM therapy (e.g., skin reaction, dysregulation of thermoregulation, etc)

Any contraindication to dexamethasone or valproic acid such as known allergies or sensitivity

Have a contraindication to NSAIDs at the oncologist’s discretion (i.e., allergy, worsening of ongoing medical problem due to NSAID, low platelet count from chemotherapy, and uncontrolled condition such as hypertension or asthma)

Patients must not have any known contraindication to CSFs prior to registration, including prior hypersensitivity to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, or tbo-filgrastim

Contraindication to test article, constituents, or required concomitant medications